Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

01-12-2015 | Meeting abstract

Case report: Cushing syndrome clinical presentation related to pigmented nodular adrenal disease

Authors: Olga Simone Nebel First, Fernanda Angeli Padula, Amine Wiener Vasconcellos Haddad, Márcio Bousada Franco, Renata Marques, Greta Barriquel Pompermaier

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Patient case report of secondary type2 diabetes description presenting the syndrome of Cushing by PPNAD. SLP, 57, born and living in São Paulo, SP, followed at the Endocrinology Clinic of a Public Hospital, diagnosed with type 2 diabetes mellitus, dyslipidemia, Hypertension and Obesity II, in regular use of medications, presenting inadequate glycemic control and blood pressure. Denied polis or hypoglycemia clinical and referred dietary control. On examination, the patient was hypertensive (BP=140/90mmHg), class II obesity (BMI 34), which is centripetal, dorsal hump, facial plethora and full moon facies. Laboratory tests in September 2014 showed deterioration of the glycemic control (FPG 129 mg/dL and HbA1c 9.1%) and LDL-cholesterol (93mg/dL). …
Metadata
Title
Case report: Cushing syndrome clinical presentation related to pigmented nodular adrenal disease
Authors
Olga Simone Nebel First
Fernanda Angeli Padula
Amine Wiener Vasconcellos Haddad
Márcio Bousada Franco
Renata Marques
Greta Barriquel Pompermaier
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A94

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine